Risk factors for hyperglycemia in COVID-19 patients treated with remdesivir.

ABSTRACT: The primary objective of this study was to investigate the factors contributing to hyperglycemic adverse events (AEs) associated with the administration of remdesivir in hospitalized patients diagnosed with coronavirus disease 2019 (COVID-19). Furthermore, the study aimed to develop a risk score model employing various machine learning approaches. A total of 1262 patients were enrolled in this investigation. The relationship between covariates and hyperglycemic AEs was assessed through logistic regression analysis. Diverse machine learning algorithms were employed for the purpose of forecasting hyperglycemia-related complications. After adjusting for covariates, individuals with a body mass index ≥23 kg/m² , those using proton pump inhibitors, cholinergic medications, or individ

SUBMITTER: Kim W 

PROVIDER: S-EPMC10766056 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature